Compare Citius Pharmaceuticals Inc (CTXR) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Quantum Computing Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Quantum Computing Inc trades at $8.35 (market cap $1.88B). The key difference: Quantum Computing Inc is far larger — about 128.4× Citius Pharmaceuticals Inc's market cap, and Quantum Computing Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | QUBT | |
|---|---|---|
Market Cap | $14.64M | $1.88B |
Sector | Health | Technology |
52-Week High | $1.82 | $24.62 |
52-Week Low | $0.53 | $6.31 |
Enterprise Value | $10.86M | $894.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Quantum Computing Inc. (QUBT) trades at $8.00, down 7.62% amid sector-wide selling pressure. The stock shows bearish technical signals with negative moving averages but oversold RSI readings. Fundamentally, the company reported a net loss of $18.67 million on minimal revenue of $682,000 in 2025, though it maintains strong analyst support with a $24.00 consensus price target representing 200% upside potential. Recent strategic acquisitions and commercial agreements highlight growth initiatives.
QUBT presents high-risk, high-reward potential with significant cash burn offset by promising technology positioning. The company's photonics-based quantum approach and government policy support provide growth catalysts, but profitability remains distant with negative margins. Investors face substantial execution risk amid competitive quantum computing landscape, though analyst consensus remains strongly bullish on long-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
